Overview

A Phase II Clinical Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd